Toggle navigation
About Us
Portfolio
News
Contact Us
Lightchain Capital
Recent News
March 09, 2023
CareVet Expands Carebnb, Offering More Paid Vacation Opportunities for Veterinarians
READ MORE
March 07, 2023
Health Tech: Erica Barnell On How Geneoscopy's Technology Can Make An Important Impact On Our Overall Wellness
READ MORE
February 28, 2023
Geneoscopy appoints Don Hardison to its Board of Directors
READ MORE
February 23, 2023
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
READ MORE
January 30, 2023
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDACâ„¢ Degrader, in BRAF V600 Mutant Solid Tumors
READ MORE
January 24, 2023
Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test
READ MORE
January 21, 2023
Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium
READ MORE
January 10, 2023
Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial
READ MORE
January 09, 2023
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
READ MORE
January 03, 2023
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
READ MORE
1
2
3
4
5
6
7
8
...
21
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2021 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group